Adults with a specific type of bladder cancer that has stopped responding to standard BCG therapy now have a federally approved treatment option for the first time. The U.S. Food and Drug Administration announced on October 14, 2026, that it had broadened the approved indications for Anktiva (nogapendekin alfa inbakicept-pmln) to cover high-grade papillary-only non-muscle invasive bladder cancer (NMIBC) that is BCG-unresponsive — a patient population that previously lacked any FDA-sanctioned therapy designed specifically for their condition.
The expanded label was granted to Altor BioScience, LLC, the FDA stated in its press announcement. Anktiva is given alongside BCG, delivered directly into the bladder. The drug had already carried approval for a related NMIBC form — carcinoma in situ (CIS) — but the new indication extends coverage to patients whose tumors are papillary in nature and have not invaded the bladder muscle.
An Unconventional Path to Approval
Rather than requiring a separate, large-scale clinical trial for the papillary-only population, the FDA based this expanded approval on evidence gathered from the earlier CIS trial, alongside scientific data showing meaningful similarities between the two cancer types. The agency noted that CIS and high-grade papillary tumors regularly appear together in the same patients, can be difficult to distinguish under a microscope, and both carry elevated risks of recurrence or progression after BCG fails.
R. Angelo de Claro, M.D., Director of the FDA Oncology Center of Excellence, explained the agency's reasoning: "We listen to patients, clinicians, and researchers, and we act when the science supports a new approach. For Anktiva, our review of the similarities between these cancers allowed us to build on the results in patients with CIS and expand treatment options for people with high-grade papillary tumors alone. This approach may also help guide the development of future treatments."
Understanding the Cancer Types Involved
NMIBC is bladder cancer that has not penetrated the bladder's muscle wall. Within this category, CIS forms as flat lesions along the bladder lining, whereas papillary tumors project outward from the lining in small, finger-like growths. High-grade variants of both types — including the papillary-only form now covered under Anktiva's label — carry a greater likelihood of spreading compared to low-grade cancers, according to the FDA.
BCG, which stimulates the immune system inside the bladder, is the standard first-line treatment for high-risk NMIBC. When that therapy fails and cancer persists or returns, patients are classified as BCG-unresponsive. The FDA said Anktiva gives the immune system an additional mechanism to attack the cancer when BCG alone has proven insufficient.
Clinical Evidence Behind the Decision
The supporting trial — registered as NCT03022825 — enrolled 77 adult patients, including some who also had papillary tumors alongside CIS, the FDA said. Among all participants, 62 percent achieved a complete response, defined as no detectable high-grade cancer during follow-up evaluations. Of those who reached a complete response, 58 percent sustained it for a minimum of 12 months, while 40 percent maintained their response for at least 24 months.
Dosing and Administration Details
Anktiva is instilled into the bladder through a catheter together with BCG. Treatment begins with once-weekly administrations over an initial six-week course, with subsequent cycles determined by how the cancer responds. The FDA indicated that the full treatment course may run for as long as 37 months.
The agency specifies that the drug must be discontinued if cancer remains after a second six-week treatment course, if the disease returns or worsens, or if a patient experiences intolerable side effects.
Reported Side Effects and Safety Warnings
Commonly reported adverse effects include painful or frequent urination, urinary urgency, blood in the urine, urinary tract infections, and muscle or joint pain, according to the FDA. Laboratory findings in some patients showed elevated creatinine and potassium levels. Chills and fever were also among the reported reactions.
The prescribing information for Anktiva carries a warning that postponing bladder surgery — whether partial or total removal — while using this drug can allow cancer to spread beyond the bladder, a complication the FDA identifies as potentially fatal.
Regulatory Guidance in the Pipeline
To give future drug developers a clear framework for applying this kind of evidence-bridging approach, the FDA said it is working to finalize its draft guidance document titled "Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment." Once finalised, the guidance is intended to outline how data from CIS patient trials may be used to support approval applications for BCG-unresponsive, high-grade papillary-only NMIBC treatments.
By the Numbers
- 77 adults enrolled in clinical trial NCT03022825
- 62% of trial participants achieved a complete response
- 58% of complete responders maintained their response for at least 12 months
- 40% of complete responders maintained their response for at least 24 months
- 6 weeks — length of the initial once-weekly treatment course
- 37 months — maximum total treatment duration
Why This Matters
Prior to this approval, patients with BCG-unresponsive, high-grade papillary-only bladder cancer had no FDA-approved therapy developed specifically for their disease type, according to the FDA. The agency's decision to bridge evidence across closely related cancer forms may also inform how future treatments for similar conditions are evaluated and approved. The planned finalisation of the FDA's draft guidance document is expected to provide drug developers with a defined pathway for pursuing comparable evidence-bridging approvals.
Source: U.S. Food and Drug Administration press announcement